While this result affirms Bimzelx’s efficacy in PsA, analysts do not believe this readout will have a notable impact on the drug’s uptake or sales.

AbbVie (ABBV) stock is in focus as UCB (UCBJY) says its Bimzelx beat Skyrizi in a head-to-head psoriatic arthritis trial. Read more here.

UCB said it’s the first time an approved biologic demonstrated superiority over an IL-23 blocker in psoriatic arthritis. Yet analysts aren’t sure how commercially impactful the results will be.

After UCB’s Bimzelx scored five approvals in just two years, the Belgian drugmaker has quickly made a blockbuster out of its ...

Belgium’s largest drugmaker UCB has announced positive topline data from the BE BOLD trial assessing Bimzelx bimekizumab) versus Skyrizi (risankizumab) in adults living with active psoriatic arthritis ...

Pooled data from PsA and axSpA extension studies provide early reassurance ...

Please provide your email address to receive an email when new articles are posted on . Hidradenitis Suppurativa Clinical Response 50 was achieved by 85.4% of patients by week 96. An approximate one ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The new Bimzelx administration and dosage is available ...

Symptom relief sustained to three years: Improvements in the stringent endpoints HiSCR75, HiSCR90, and HiSCR100 at one year were sustained to three years in 81.2%, 64.3%, and 50.1% of patients, ...

Reduction of draining tunnels sustained to three years: Of patients who had at least one draining tunnel at baseline, 48.2% had none at one year, and 62.9% at three years* – indicating sustained ...

Bimekizumab was associated with clinically meaningful improvements in HS signs and symptoms compared with placebo. The Food and Drug Administration (FDA) has approved Bimzelx ® (bimekizumab-bkzx) for ...

ATLANTA, Sept. 17, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced three-year data from the BE HEARD trials for BIMZELX® (bimekizumab-bkzx) in adults with ...